| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 3 | +26,765 | 9.5% | $9.04 | +$241,896 |
| Sells | 3 | -253,800 | 90% | $16.42 | -$4,167,399 |
| Net | 0 | -227,035 | -81% | -$3,925,502 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Michael A. Metzger | Chief Executive Officer, Director | $19,328,457 | -$3,165,629 | -14% | 09 Feb 2026 |
| Steve M. Sabus | Chief Commercial Officer | $5,685,614 | 05 Dec 2022 | ||
| Keith A. Goldan | Chief Financial Officer | $5,363,681 | -$126,670 | -2.3% | 09 Feb 2026 |
| Dennis Podlesak | Director | $5,037,420 | -$875,100 | -15% | 04 Feb 2026 |
| Nicholas A.J. Botwood | Head of R&D, CMO | $4,955,637 | +$105,826 | +2.2% | 04 Feb 2026 |
| Neil Gallagher | President, Head of R&D | $2,938,138 | 10 Feb 2025 | ||
| Catherine Madigan | Chief Medical Officer | $2,842,807 | 02 Feb 2023 | ||
| Keith Katkin | Director | $2,605,240 | +$91,120 | +3.6% | 04 Feb 2026 |
| Pierre Legault | Director | $2,395,140 | 04 Feb 2026 | ||
| Jennifer Jarrett | Director | $2,395,140 | 04 Feb 2026 | ||
| Martin H. Huber Jr. | Director | $2,164,030 | +$44,950 | +2.1% | 04 Feb 2026 |
| William Meury | Director | $1,802,682 | 05 Feb 2025 | ||
| Aleksandra Rizo | Director | $1,029,490 | 04 Feb 2026 | ||
| Michael L. Meyers | SVP, Chief Medical Officer | $873,600 | 02 Feb 2022 | ||
| Briggs Morrison | Director | $636,283 | 07 Feb 2024 | ||
| Fabrice Egros | Director | $584,483 | 02 Feb 2022 | ||
| Alexander Nolte | Chief Accounting Officer | $439,343 | 02 Feb 2023 | ||
| Peter Ordentlich | Chief Scientific Officer | 15 Feb 2023 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|